Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
Breaking Down Molly: Swiss University Studies How MDMA's Components Might Affect Humans
October 04, 2022
Tickers
MDMA
MNMD
Tags
Market News
Phase 1 Trial
Dr/ Miri Halperin Wernli
From
Benzinga
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
June 30, 2022
Tickers
CDAK
Tags
Market News
Phase 1 Trial
News
From
Benzinga
eFFECTOR's Cancer Therapy Achieves Two Partial Responses In Early-Stage Study
June 06, 2022
Tickers
EFTR
Tags
Market News
News
Phase 1 Trial
From
Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
June 06, 2022
Tickers
BNTX
MRK
RHHBF
RHHBY
Tags
Biotech
Market News
RHHBY
From
Benzinga
Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial
May 18, 2022
Tickers
KROS
Tags
Market News
News
Phase 1 Trial
From
Benzinga
Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
May 12, 2022
Tickers
CRBU
Tags
Biotech
General
Phase 1 Trial
From
Benzinga
FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron
April 25, 2022
Tickers
SRNE
Tags
SRNE
General
News
From
Benzinga
Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine
April 14, 2022
Tickers
SNY
Tags
Health Care
Biotech
Briefs
From
Benzinga
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
April 14, 2022
Tickers
ABBV
GMAB
Tags
Market News
Phase 1 Trial
News
From
Benzinga
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
April 12, 2022
Tickers
COCP
Tags
Movers
Trading Ideas
Health Care
From
Benzinga
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
April 12, 2022
Tickers
RPTX
Tags
RPTX
Biotech
General
From
Benzinga
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump
April 12, 2022
Tickers
BCDA
Tags
Movers
Briefs
Trading Ideas
From
Benzinga
IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
April 11, 2022
Tickers
BMY
IOBT
Tags
Market News
Phase 1 Trial
News
From
Benzinga
BioNTech Posts Interim Phase 1 Data From CAR-T/Cancer Vaccine Combo In Solid Tumors
April 11, 2022
Tickers
BNTX
Tags
Biotech
Health Care
BNTX
From
Benzinga
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
April 11, 2022
Tickers
AIM
Tags
Movers
Trading Ideas
Health Care
From
Benzinga
Zentalis Pharma Posts Initial Clinical Data On Its Wee1 Inhibitor In Ovarian Cancer
April 11, 2022
Tickers
ZNTL
Tags
Benzinga
General
Small Cap
From
Benzinga
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
April 07, 2022
Tickers
VYNE
Tags
Market News
Phase 1 Trial
News
From
Benzinga
Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis
April 07, 2022
Tickers
MCRB
Tags
ulcerative colitis
Biotech
General
From
Benzinga
VBI Vaccines To Start Clinical Study Of Pan-Coronavirus Vaccine Candidate This Year
April 05, 2022
Tickers
VBIV
Tags
Preclinical Phase
General
COVID/19 Coronavirus
From
Benzinga
Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model
March 31, 2022
Tickers
MITO
Tags
Huntington's Disease
Penny Stocks
Biotech
From
Benzinga
Portage Biotech Shares Encouraging Preliminary Safety Data From Lead iNKT Agonists Program In Cancer Patients
March 31, 2022
Tickers
BMY
MRK
PRTG
Tags
Benzinga
MRK
Health Care
From
Benzinga
EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal
March 31, 2022
Tickers
LGVN
Tags
Benzinga
Alzheimer's disease
Alzheimer’s
From
Benzinga
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
March 30, 2022
Tickers
CVAC
GSK
Tags
CVAC
Health Care
COVID/19 Vaccine
From
Benzinga
Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study
March 29, 2022
Tickers
SYN
Tags
Health Care
Biotech
Briefs
From
Benzinga
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
March 28, 2022
Tickers
BIIB
IONS
Tags
General
Market News
Phase 1 Trial
From
Benzinga
Pluristem's PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients
March 23, 2022
Tickers
PSTI
Tags
Benzinga
General
Market News
From
Benzinga
Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate
March 22, 2022
Tickers
ALGS
Tags
ALGS
Market News
Phase 1 Trial
From
Benzinga
Why ORIC Pharmaceuticals Shares Are Plunging Today
March 22, 2022
Tickers
ORIC
Tags
Guidance
Biotech
Market News
From
Benzinga
Terns Reports Topline Results from Early-Stage NASH Study
March 22, 2022
Tickers
TERN
Tags
Phase 1 Trial
News
Market News
From
Benzinga
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
March 21, 2022
Tickers
PULM
Tags
Movers
Briefs
Health Care
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.